Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study to investigate the efficacy and safety of ZK 219477 [sagopilone] as first line therapy in chemotherapy naive patients with extensive disease (ED) stage small cell lung cancer (SCLC).

Next Previous
X
Search
Trial Profile

Phase II study to investigate the efficacy and safety of ZK 219477 [sagopilone] as first line therapy in chemotherapy naive patients with extensive disease (ED) stage small cell lung cancer (SCLC).

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Jan 2016

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sagopilone (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Bayer

    • Most Recent Events

    • 30 Dec 2015 Status changed from completed to discontinued as per ClinicalTrials.gov record.
    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2005-000597-53).
    • 12 May 2009 Company added as trial sponsor and affiliate as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top